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1. Introduction
Ultrasound techniques represent easy and useful diagnostic tools able to detect cardiac mor‐
phological and functional damage.
Transthoracic echocardiography is a reliable, cheap and non-invasive technique that allows
an accurate evaluation of valvular abnormalities, pericardial diseases and ventricular wall
motion defects, while Doppler analysis is useful to study left ventricular diastolic filling, val‐
vularfuctioning and pulmonary pressures. Rexhepaj et al [1] found significant differences in
early diastolic flow velocity (E), atrial flow velocity (A) and E/A ratio in rheumatoid arthritis
(RA) patients compared to the control group, suggesting that a subclinical impairment of
left and right ventricular function is present in RA patients, when left ventricular thickness,
dimensions and myocardial performance indexes were still normal.
A new clinical application of ultrasound imaging is represented by the transthoracic dipyri‐
damole stress echocardiography with coronary flow reserve (CFR) evaluation. CFR is as‐
sessed in the distal left anterior descending coronary artery (LAD) defined by the ratio
between peak diastolic velocity during stress and at baseline(Fig. 1-2). It is a highly sensitive
(>90%) diagnostic marker for coronary artery disease (CAD)[2, 3] and, when associated with
the evaluation of the regional wall motion analysis, it becomes also highly specific [4]. In lit‐
erature reports, a value of CFR < 2 has been shown to accurately predict the presence of cor‐
onary stenosis. In absence of epicardial coronary stenosis, an abnormal CFR may reflect an
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impaired coronary microcirculation in patients with reperfused myocardial infarct, arterial
hypertension with or without left ventricular hypertrophy, diabetes mellitus, hypercholes‐
terolemia, syndrome X, hypertrophic cardiomyopathy and other diseases [5].The assessment
of CFR has also a prognostic value, so that a reduced CFR correlates with a negative progno‐
sis [6]. Recently, new evidence underlined that not only the binary (normal-abnormal) re‐
sponse in CFR but the continuous spectrum of CFR value is a strong independent
prognostic predictor in patients with known or suspected CAD [7].
Figure 1. Distal left anterior descending (LAD) flow at color-Doppler.
Hirata et al [8] found a significant reduction of CFR in premenopausal women with SLE
compared with age- and sex-matched controls. They concluded that microvascular impair‐
ment in SLE could be explained by functional alteration of endothelium which is responsible
for the decrease vasodilation in response to pharmacological stress.
Turiel et al. 9 detected a significant impairment of CFR in 25 early RA patients, with disease
duration less than 1 year and without any anti-rheumatic therapy. The reduced CFR in ab‐
sence of wall motion abnormalities at rest and during pharmacological stress showed a coro‐
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nary microcirculation involvement present in early RA and was associated with endothelial
dysfunction.
Tissue Doppler Imaging (TDI) representsa new imaging modality which allows the meas‐
urement of myocardial velocities. Till now, TDI has been considered a reliable tool for the
assessment of myocardial deformation, but this method is limited by angle-dependency and
only deformation along the ultrasound beam can be derived from velocities, while myocar‐
dium deforms simultaneously in 3 dimensions [10]. Recently, Birdane et al [11] demonstrat‐
ed that RA patients had a significant impairment of TDI biventricular diastolic functional
parameters compared to healthy controls depending on age and use of steroids. To over‐
come TDI limitations, speckle tracking analysis has been introduced to evaluate myocardial
strain along the longitudinal, circumferential and radial axis [12].
Figure 2. Doppler sampling of LAD: ratio between peak diastolic velocity during stress and at baseline.
Another very useful application of echocardiography in systemic autoimmune diseases is
the echo transesophageal approach which is widely recognized as more sensitive than the
transthoracic evaluation for the detection of valvular lesions [13] and identification of intra‐
cardiac masses.
In particular, Turiel et al [14] observed a large prevalence (61%) of valvular thickening or
vegetations and/or potential embolic sources by transesophageal echocardiographic ap‐
proach in 56 patients with primary antiphospholipid syndrome followed up for 5 years.
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2. Utility of coronary flow reserve assessment in systemic autoimmune
diseases
Patients suffering from systemic autoimmune diseases (SADs), especially RA, present high‐
er risk of acute myocardial infarction and stroke [15], correlated with disease duration [16]
with higher frequency of silent myocardial infarction and sudden death compared to gener‐
al population [17]. This increase in cardiovascular (CV) risk seems not depending on tradi‐
tional risk factors, thus suggesting a dominating role of RA-related risk factors [18, 19].
During these last years, attempts of explaining the accelerated atherosclerosis pathogenic
pathways in RA were made; Attention particularly focused importance of chronic systemic
inflammatory processwith high pro-inflammatory cytokines plasmatic levels. Presence of
pro-atherogenic alterations such as dislipidemy, insulin-resistance, trombofilia and oxida‐
tive stress look favoring development of endothelial dysfunction that may be the initial
stage of the atherosclerotic process [20, 21]. Arosio et al. [22], showed a reduced vasodilata‐
tion endothelium-dependant, changes in micro circle reactivity and an increased arterial
stiffness in RA female patients.
Today non invasive evaluation of carotid median intimal thickness (IMT) is considered an
early atherosclerosis clinical marker [23]. Kumeda et al. [24] observed in RA patients an in‐
creased IMT of common carotid and femoral artery, related to disease severity and duration.
According to these evidences, Ciftci et al. [25] confirmed increased IMT and presence of re‐
duced coronary flow reserve (CFR) in RA patients, correlating CV risk to disease duration.
Moreover, Chung et al. [26], studied extension of coronary calcifications with CT, showing
that patient with a long history of RA presents greater prevalence and severity of coronary
calcifications compared to patients with early RA, also correlated with smoking and increase
eritrosedimentation rate (ESR).
Nowadays, trans-thoracic echocardiographic evaluation of CFR by pharmacological stress
(adenosine or dipyridamole)is considered a very useful exam as diagnose marker highly
sensible (>90%) for coronary disease [27]. If associated with LV regional kinesis evaluation,
acquires high specificity too. CFR value< 2 measured about at middle-distal tract of left ante‐
rior descending artery can accurately predict the presence of coronary significative stenosis.
If epicardial vessels are free from significant stenosis a reduced CFR can be evidence of an
alteration in coronary microcirculation in patients with reperfused myocardial infarction,
high blood pressure with or without LV hypertrophy, diabetes mellitus, hypercholesterole‐
mia, X syndrome, hypertrophic cardiomyopathy and collagen diseases. CFR measure has
prognostic value in different pathologic conditions too[28].
Turiel et al. [29] showed a statistically significative variation of CFR among RA patients re‐
lated with disease duration.
Endothelium function can be also studied through measure of asymmetric dymethilargi‐
nine(ADMA) plasmatic levels. Many clinical evidences support a close association between
ADMA level and CV involvement in patients autoimmune diseases [30].
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Higher ADMA plasmatic levels are reported in many conditions associated with high CV
risk such as hypercholesterolemia, hypertriglyceridemia [31], peripheral artery disease [32],
diabetes mellitus type II [33], acute coronary syndrome [34], chronic renal failure [35]. More‐
over, Surdacki et al [36] evidenced in RA patient an association between high ADMA plas‐
matic levels and increased IMT at common carotid artery. Turiel et al. [37]observed an
inverse correlation between ADMA and CFR in early stages of RA thus indicating a subclin‐
ical heart involvement already present at the beginning of the development of the disease.
Many clinical trials evidenced potential effects against atherosclerosis of therapies lead with
disease modifying anti-rheumatic drugs (DMARDs), going beyond the simple control of in‐
flammatory process and of disease activity (Tab. 1). In particular Hurlimann et al. [38]
showed that anti-TNFα can not only reduce disease activity indexes, but also increase endo‐
thelial function in RA. Moreover, Sitia et al. [39] observed that long time treatment with
DMARDs can reverse endothelial dysfunction, in early stages of disease.
Table 1. Disease modifying anti-rheumatic drugs (DMARDs) in common use. (From American College of
Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid
arthritis. Arthritis Rheum 2002; 46: 328-46, modified).
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In addition, Mäki-Petäjä et al. [40] in a recent study confirmed the efficacy of associating
ezetimibe and simvastatin  in  reducing the  inflammatory process,  but  also  in  improving
aortic  stiffness  in  RA.  Anyway,  the  possible  validation  of  efficacy  of  the  therapy  with
statin and/or biological drugs in modifying the evolution of atherosclerosis needs further
perspective clinical trials.
3. Conclusions
Subclinical CV involvement related to specific and non-specific risk factors is frequent in
systemic autoimmunity diseases. It begins rapidly after the onset of the disease and pro‐
gresses with disease duration. All cardiac structures may be affected, and the cardiac com‐
plications include a variety of clinical manifestations. As CV involvement is associated with
an unfavorable prognosis, the early detection of subclinical cardiac involvement in asympto‐
matic SADs patients is essential and then modern techniques nowhere existing and in this
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